Botox label expanded to include spasticity in children

24 June 2019

Allergan (NYSE: AGN) has won an expansion to the US label for Botox (onabotulinumtoxinA), to treat children with upper limb spasticity, under the US regulator’s Priority Review scheme.

The approval comes amid rumors that the firm could soon be broken up, with its therapeutics and cosmetics divisions becoming separate companies.

With concerns over commercial underperformance and a thin late-stage pipeline, some investors have been agitating for change in recent months. Chief executive Brent Saunders has been forced to agree to a management shake-up, but only after his tenure comes to an end.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK